Federico Pea

Full Professor of Pharmacology

University of Bologna

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

ORCID

Google Scholar

About

Federico Pea is a Full Professor of Pharmacology at the University of Bologna, Italy. His research focuses on pharmacokinetics and pharmacodynamics, particularly in relation to antibiotic resistance in bacteria such as Pseudomonas aeruginosa and Klebsiella pneumoniae. Recent publications include studies on TDM-guided therapies and continuous infusion strategies for optimizing antibiotic treatment in critically ill patients.

Federico Pea

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Rapid Emergence of Cefiderocol Resistance Associated with Mutation of EnvZ Gene in a VIM-Producing ST307 Klebsiella pneumoniae Strain

Targeting Pseudomonas aeruginosa resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion

TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient

TDM-Based Approach for Properly Managing Intravenous Isavuconazole Treatment in a Complex Case Mix of Critically Ill Patients

Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow

Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data

A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?

Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis

Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis

Is it Time to Move From Intermittent to Continuous Infusion Administration of Vancomycin?

An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients

Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales

Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis

Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients

Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT

In reply to the Letter to the Editor regarding “Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis”

A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue

Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study

Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment

Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin

Safety of high loading doses of teicoplanin: POSY-TEICO, a prospective, multicentre, observational study

Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection due to OXA-181-producing Klebsiella pneumoniae

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections

Comment on: pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections

A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections

Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring

A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study

Collaborators (8)

Mario VENDITTI

Manjunath Pai

Claudio Foschi

Vincent H Tam

Alessandra Oliva

Paolo Gaibani

Stefano Di Bella

Ettore Rocchi

How do I reach out?

Meet Kite AI